Skip to main content
. 2013 Jul 20;16(7):345–352. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2013.07.03

2.

吉非替尼组和厄洛替尼组疗效

Tumor response in gefitinib-treated and erlotinib-treated patients

Response Gefitinib group (n=30) Erlotinib group (n=31) P
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; DCR: disease control rate; RR: response rate.
CR 0 0
PR 3 7
SD 15 16
PD 12 8
DCR 60.00% 74.19% 0.237, 8
RR 10.00% 22.58% 0.300, 6